Psychopharmacological prospects

Leonard BE (1985). Animal models of depression and the detection of antidepressants. In SD Iversen (ed.), Psychopharmacology Recent Advances and Future Prospects (pp. 33—43). Oxford University Press, Oxford, UK. 

Riddle, M.A., Labellarte, M.J., and Walkup, J.T. (1998) Pediatric psychopharmacology problems and prospects. / Child Adolesc Psychopharmacol 8 87-97. 

As may be expected, studies of antidepressants in treatment of ADHD have not shown a differential effect in ADHD children with or without conduct disorder, depression, or anxiety (Biederman et ah, 1993b). While DMI-treated ADHD children showed a substantial reduction in depressive symptoms compared with placebo-treated patients (Biederman et ah, 1989), DMI appears not to be as powerful an antidepressant in children as the SSRls. (Bostic et ah, 1999). The safety and efficacy of combined SSRl and stimulant pharmacotherapy has been addressed in two open studies and is currently being evaluated in a prospective study conducted by the Resarch Units in Pediatric Psychopharmacology (RUPP) Network (B. Vitiello, personal communication). 

Klerman. G.L. Future prospects for clinical psychopharmacology. In Meltzer, ELY. (ed.) Psvchopharmacologv the Third Generation of Progress. Raven, New York, 1987, pp. 1699-1705. 

Martin A, Scahill L, Anderson GM, Aman M, Arnold LE, McCracken J, McDougle CJ, Tierney E, Chuang S, Vitiello B (The Research Units on Pediatric Psychopharmacology Autism Network). Weight and lep-tin changes among risperidone-treated youths with autism 6-month prospective data. Am J Psychiatry 2004 161 1125-7. 

Himmich, H. E. 1958, Prospects in psychopharmacology, in The New Chemotherapy in Mental Illness, H. L. Gordon, ed., Peter Owen, London. 

National Institute of Mental Health and the Food and Drug Administration. (1995, January 24—25). Psychopharmacology in child and adolescents Current problems, future prospects [Conference transcript]. Washington, DC. 

Maddock C, Baita A, Orru MG, Sitzia R, Costa A, Muntoni E, Farci MG, Carpiniello B, Pariante CM. Psychopharmacological treatment of depression, anxiety, irritability and insomnia in patients receiving interferon-alpha a prospective case series and a discussion of biological mechanisms. J Psychopharmacol 2004 18 41-6. 

Kostis JB, Rosen RC, Holzer BC, Randolph C, Taska LS, Miller MH. CNS side effects of centrally-active antihyper-tensive agents a prospective, placebo-controlled study of sleep, mood state, and cognitive and sexual function in hypertensive males. Psychopharmacology (Berl) 1990 102(2) 163-70. 

Nagy, L. M., C. A. Morgan, S. M. Southwick, and D. S. Cheimey. 1993. Open prospective trial of fluoxetine for post-traumatic stress disorder. Journal of Clinical Psychopharmacology 13 107-13. 

The neurotransmitter transporter family has provided many valuable targets for psychopharmacology. There is every prospect that this will continue. It might seem that the monoamine transporters had already been fully exploited, but the reemergence of NET-specific antidepressants and the possible applications of selective inhibitors of DAT suggest that there may still be room for innovation even in such a crowded field. 

Rendell PG, Mazur M, Henry JD. Prospective memory impairment in former users of methamphetamine. Psychopharmacology 2009 204 609-16. 

---